Dare Bioscience
cream phase ongoing phase clinical study aims to evaluate cream placebo over weeks of dosing following both a non drug and placebo run in period compares cream placebo used in patients home setting primary patient reported outcome pro instruments to measure improvement in localized genital sensations of arousal and reduction in related distress several exploratory efficacy will be measured and could become additional measurements of efficacy in a future phase program topline data of phase respond study targeted for | Dare Bioscience
Company
Deck Type
Sector
Industry
Deck date
February 2023
Slide
34 of 54
Similar slides by Dare Bioscience
See diffirences between slides (animation)
Investor Presentation
October 2022
cream phase ongoing phase clinical study aims to evaluate cream placebo over weeks of dosing following both a non drug and placebo run in period study enrollment expected to complete in with approximately subjects topline data of phase respond study targeted for | Dare Bioscience
Related slides by other companies
BioAtla
Investor Presentation
January 2024
phase cab in stage refractory melanoma | BioAtla
NeuroSense Therapeutics
Investor Presentation
October 2024
road phase study design | NeuroSense Therapeutics
NeuroSense Therapeutics
Investor Presentation
October 2024
highlights | NeuroSense Therapeutics
Compass Therapeutics
Investor Presentation
May 2022
phase combination study status | Compass Therapeutics
Other recent decks by Dare Bioscience
See all presentations (5 decks)
Results
November 2023
Investor Presentation
August 2023
Investor Presentation
July 2023
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights